Compare PGEN & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | SAM |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2013 | 1996 |
| Metric | PGEN | SAM |
|---|---|---|
| Price | $5.64 | $183.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 11 |
| Target Price | $8.33 | ★ $233.70 |
| AVG Volume (30 Days) | ★ 5.5M | 273.7K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.45 |
| EPS | ★ N/A | N/A |
| Revenue | $230,981,000.00 | ★ $1,964,994,000.00 |
| Revenue This Year | $1,115.92 | $1.02 |
| Revenue Next Year | $81.04 | $1.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.47 | $158.68 |
| 52 Week High | $6.04 | $264.46 |
| Indicator | PGEN | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 51.48 |
| Support Level | $3.32 | $170.14 |
| Resistance Level | N/A | $186.99 |
| Average True Range (ATR) | 0.34 | 6.44 |
| MACD | 0.06 | 1.52 |
| Stochastic Oscillator | 75.46 | 60.20 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.